Biomarkers in sarcoidosis: a review

References

• Ahmadzai H, Wakefield D, Thomas PS. The potential of the immunological markers of sarcoidosis in exhaled breath and peripheral blood as future diagnostic and monitoring techniques. Inflammopharmacology. 2011;19(2):55–68.
   Google Scholar
• Gerke AK, Hunninghake G. The immunology of sarcoidosis. Clin Chest Med. 2008;29(3):379–390.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Fulmer JD, Young RC Jr, Gadek JE, Crystal RG. Localization of the immune response in sarcoidosis. Am Rev Respir Dis. 1979;120(1):49–57.
   Google Scholar
• Mathew S, Bauer KL, Fischoeder A, Bhardwaj N, Oliver SJ. The anergic state in sarcoidosis is associated with diminished dendritic cell function. J Immunol. 2008;181:746–755.
   PubMed Web of Science ®Google Scholar
• Grunewald J, Eklund A. Role of CD4+ T cells in sarcoidosis. Proc Am Thorac Soc. 2007;4(5):461–464.
   PubMedGoogle Scholar
• Mert A, Bilir M, Ozaras R, Tabak F, Karayel T, Senturk H. Results of hepatitis B vaccination in sarcoidosis. Respiration. 2000;67(5):543–545.
   Web of Science ®Google Scholar
• Statement on Sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG), adapted by the ATS Board of Directors and by the ERS Executive Committee. Am J Respir Crit Care Med. 1999;160(2):736–755.
   PubMedGoogle Scholar
• Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1885–1889.
   PubMed Web of Science ®Google Scholar
• Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–2165.
   PubMed Web of Science ®Google Scholar
• Ozsu S, Ozcelik N, Oztuna F, Ozlu T. Prognostic value of red cell distribution width in patients with sarcoidosis. Clin Respir J. Epub January 9, 2014.
   Google Scholar
• Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologist’s perspective. Am J Kidney Dis. 2006;48(5):856–870.
   Web of Science ®Google Scholar
• Herbort CP, Rao NA, Mochizuki M; members of the Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop on Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17(3):160–169.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–173.
   PubMed Web of Science ®Google Scholar
• Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132(6):1949–1953.
   PubMed Web of Science ®Google Scholar
• Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res. 2014;4(1):1.
   Google Scholar
• Ahmadzai H, Cameron B, Chui JJ, Lloyd A, Wakefield D, Thomas PS. Peripheral blood responses to specific antigens and CD28 in sarcoidosis. Respir Med. 2012;106(5):701–709.
   Web of Science ®Google Scholar
• Seyhan EC, Günlüoglu G, Altin S, et al. Results of tetanus vaccination in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(1):3–10.
   Web of Science ®Google Scholar
• Gupta D, Chetty M, Kumar N, Aggarwal AN, Jindal SK. Anergy to tuberculin in sarcoidosis is not influenced by high prevalence of tuberculin sensitivity in the population. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(1):40–45.
   Web of Science ®Google Scholar
• Amicosante M. IGRAs for tuberculosis in sarcoidosis patients: is the immune response to mycobacteria helpful in the differential diagnosis or still a confounding factor? Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):85–86.
   Web of Science ®Google Scholar
• Gupta D, Kumar S, Aggarwal AN, Verma I, Agarwal R. Interferon gamma release assay (QuantiFERON-TB Gold In Tube) in patients of sarcoidosis from a population with high prevalence of tuberculosis infection. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):95–101.
   PubMed Web of Science ®Google Scholar
• Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med. 2007;175(7):737–742.
   PubMed Web of Science ®Google Scholar
• Hörster R, Kirsten D, Gaede KI, et al. Antimycobacterial immune responses in patients with pulmonary sarcoidosis. Clin Respir J. 2009;3(4):229–238.
   Web of Science ®Google Scholar
• Chen ES, Wahlström J, Song Z, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol. 2008;181(12):8784–8796.
   PubMed Web of Science ®Google Scholar
• Oswald-Richter K, Culver DA, Hawkins C, et al. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun. 2009;77(9):3740–3748.
   PubMed Web of Science ®Google Scholar
• Oswald-Richter K, Beachboard DC, Zhan X, et al. Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis. Respir Res. 2010;11:161.
   PubMed Web of Science ®Google Scholar
• Drake WP, Dhason MS, Nadaf M, et al. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun. 2007;75(1):527–530.
   PubMed Web of Science ®Google Scholar
• Dubaniewicz A. Mycobacterium tuberculosis heat shock proteins and autoimmunity in sarcoidosis. Autoimmun Rev. 2010;9(6):419–424.
   Web of Science ®Google Scholar
• Hajizadeh R, Sato H, Carlisle J, et al. Mycobacterium tuberculosis antigen 85A induces Th-1 immune responses in systemic sarcoidosis. J Clin Immunol. 2007;27(4):445–454.
   PubMed Web of Science ®Google Scholar
• Iannuzzi MC. Advances in the genetics of sarcoidosis. Proc Am Thorac Soc. 2007;4:457–460.
   Google Scholar
• Reichel H, Koeffler HP, Barbers R, Norman AW. Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J Clin Endocrinol Metab. 1987;65(6):1201–1209.
   Web of Science ®Google Scholar
• Inui N, Murayama A, Sasaki S, et al. Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med. 2001;110(9):687–693.
   Web of Science ®Google Scholar
• Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med. 2010;31(4):474–484.
   PubMed Web of Science ®Google Scholar
• Niimi T, Tomita H, Sato S, et al. Vitamin D receptor gene polymorphism in patients with sarcoidosis. Am J Respir Crit Care Med. 1999;160(4):1107–1109.
   Web of Science ®Google Scholar
• Niimi T, Tomita H, Sato S, et al. Vitamin D receptor gene polymorphism and calcium metabolism in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(3):266–269.
   Web of Science ®Google Scholar
• Baughman RP, Janovcik J, Ray M, Sweiss N, Lower EE. Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):113–120.
   PubMed Web of Science ®Google Scholar
• Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem. 2003;49(9):1510–1517.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Murphy FT, Gilliland WR, Hnatiuk W. Osseous disease in patients with pulmonary sarcoidosis and musculoskeletal symptoms. Respir Med. 2000;94(3):228–232.
   Web of Science ®Google Scholar
• Greenberg G, James DG, Feizi T, Bird R. Serum-proteins in sarcoidosis. Lancet. 1964;2(7373):1313–1315.
   Google Scholar
• Drent M, Wirnsberger RM, de Vries J, van Dieijen-Visser MP, Wouters EF, Schols AM. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J. 1999;13(4):718–722.
   Web of Science ®Google Scholar
• Hind CR, Flint KC, Hudspith BN, Felmingham D, Brostoff J, Johnson NM. Serum C-reactive protein concentrations in patients with pulmonary sarcoidosis. Thorax. 1987;42(5):332–335.
   Web of Science ®Google Scholar
• Spagnolo P, Grunewald J. Recent advances in the genetics of sarcoidosis. J Med Genet. 2013;50(5):290–297.
   PubMed Web of Science ®Google Scholar
• Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC. The BTNL2 gene and sarcoidosis susceptibility in African Americans and whites. Am J Hum Genet. 2005;77(3):491–499.
   PubMed Web of Science ®Google Scholar
• Klein JT, Horn TD, Forman JD, Silver RF, Teirstein AS, Moller DR. Selection of oligoclonal Vβ-specific T cells in the intradermal response to Kveim-Siltzbach reagent in individuals with sarcoidosis. J Immunol. 1995;154:1450–1460.
   PubMed Web of Science ®Google Scholar
• Bloom CI, Graham CM, Berry MP, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One. 2013;8(8):e70630.
   PubMed Web of Science ®Google Scholar
• Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006;203(2):359–370.
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med. 2003;253:18–30.
   PubMed Web of Science ®Google Scholar
• Ten Berge B, Paats MS, Bergen IM, et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology. 2012;51(1):37–46.
   PubMed Web of Science ®Google Scholar
• Judson MA, Marchell RM, Mascelli M, et al. Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. J Am Acad Dermatol. 2012;66(6):901–910.
   Web of Science ®Google Scholar
• Olejniczak K, Kasprzak A. Biological properties of interleukin 2 and its role in pathogenesis of selected diseases: a review. Med Sci Monit. 2008;14(10):RA179–RA189.
   Web of Science ®Google Scholar
• Ziegenhagen MW, Rothe ME, Schlaak M, Müller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J. 2003;21(3):407–413.
   PubMed Web of Science ®Google Scholar
• Grutters JC, Fellrath JM, Mulder L, Janssen R, van den Bosch JM, van Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest. 2003;124(1):186–195.
   PubMed Web of Science ®Google Scholar
• Keicho N, Kitamura K, Takaku F, Yotsumoto H. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest. 1990;98(5):1125–1129.
   PubMed Web of Science ®Google Scholar
• Prasse A, Katic C, Germann M, Buchwald A, Zissel G, Müller-Quernheim J. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med. 2008;177(3):330–336.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Mazzi A, Rottoli P. Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med. 2008;29(3):445–458.
   PubMed Web of Science ®Google Scholar
• Selroos O, Klockars M. Relation between clinical stage of sarcoidosis and serum values of angiotensin converting enzyme and beta2- microglobulin. Sarcoidosis. 1987;4(1):13–17.
   Google Scholar
• Mornex JF, Revillard JP, Vincent C, Deteix P, Brune J. Elevated serum beta 2-microglobulin levels and C1q-binding immune complexes in sarcoidosis. Biomedicine. 1979;31(7):210–213.
   Google Scholar
• Parrish RW, Williams JD, Davies BH. Serum beta-2-microglobulin and angiotensin-converting enzyme activity in sarcoidosis. Thorax. 1982;37(12):936–940.
   Web of Science ®Google Scholar
• Baughman RP, Lower, EE. Fungal infections as a complication of therapy for sarcoidosis. QJM. 2005;98(6):451–456.
   PubMed Web of Science ®Google Scholar
• Fehrenbach H, Zissel G, Goldmann T, et al. Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis. Eur Respir J. 2003;21(3):421–428.
   PubMed Web of Science ®Google Scholar
• Müller-Quernheim J. Sarcoidosis: Immunopathogenetic concepts and their clinical application. Eur Respir J. 1998;12(3):716–738.
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Müller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med. 1997;156(5):1586–1592.
   PubMed Web of Science ®Google Scholar
• Zissel G, Prasse A, Müller-Quernheim J. Immunologic response of sarcoidosis. Semin Respir Crit Care Med. 2010;31(4):390–403.
   PubMed Web of Science ®Google Scholar
• Medica I, Kastrin A, Maver A, Peterlin B. Role of genetic polymorphisms in ACE and TNF-α gene in sarcoidosis: a meta analysis. J Hum Genet. 2007;52(10):836–847.
   PubMed Web of Science ®Google Scholar
• Semenzato G, Bortoli M, Brunetta E, Agostini C. Chapter 4. Immunology and pathophysiology. Eur Respir Mon. 2005;32:49–63.
   Google Scholar
• Prasse A, Zissel G, Lützen N, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010;182(4):540–548.
   PubMed Web of Science ®Google Scholar
• Goodwin A, Jenkins, G. Role of integrin-mediated TGFβ activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans. 2009;37(4):849–854.
   PubMed Web of Science ®Google Scholar
• Zissel G, Homolka J, Schlaak J, Schlaak M, Müller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med. 1996;154(3 Pt 1):713–719.
   PubMed Web of Science ®Google Scholar
• Kruit A, Grutters JC, Ruven HJ, et al. Transforming growth factor-β gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest. 2006;129(6):1584–1591.
   PubMed Web of Science ®Google Scholar
• Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207–215.
   PubMed Web of Science ®Google Scholar
• Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol. 1998;28(11):3696–3705.
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Manabe K, Kishi J, et al. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin Exp Immunol. 2007;149(2):317–326.
   PubMed Web of Science ®Google Scholar
• Su R, Nguyen ML, Agarwal MR, et al. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir Res. 2013;14(1):121.
   Google Scholar
• Geyer AI, Kraus T, Roberts M, et al. Plasma level of interferon γ induced protein 10 is a marker of sarcoidosis disease activity. Cytokine. 2013;64(1):152–157.
   Web of Science ®Google Scholar
• Busuttil A, Weigt SS, Keane MP, et al. CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. Eur Respir J. 2009;34(3):676–686.
   Web of Science ®Google Scholar
• Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–686.
   PubMed Web of Science ®Google Scholar
• Iida K, Kadota J, Kawakami K, Matsubara Y, Shirai R, Kohno S. Analysis of T cell subsets and β chemokines in patients with pulmonary sarcoidosis. Thorax. 1997;52(5):431–437.
   Web of Science ®Google Scholar
• Oshima M, Maeda A, Ishioka S, Hiyama K, Yamakido M. Expression of C-C chemokines in bronchoalveolar lavage cells from patients with granulomatous lung diseases. Lung. 1999;177(4):229–240.
   Web of Science ®Google Scholar
• Petrek M, Kolek V, Szotkowská J, du Bois RM. CC and C chemokine expression in pulmonary sarcoidosis. Eur Respir J. 2002;20(5):1206–1212.
   Web of Science ®Google Scholar
• Palchevskiy V, Hashemi N, Weigt SS, et al. Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis. Fibrogenesis Tissue Repair. 2011;4:10.
   PubMedGoogle Scholar
• Pardigol A, Forssmann U, Zucht HD, et al. HCC–2, a human chemokine: gene structure, expression pattern, and biological activity. Proc Natl Acad Sci U S A. 1998;95(11):6308–6313.
   Web of Science ®Google Scholar
• Arakelyan A, Kriegova E, Kubistova Z, et al. Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis. Clin Exp Immunol. 2009;155(3):457–465.
   Web of Science ®Google Scholar
• Cappello P, Caorsi C, Bosticardo M, et al. CCL16/LEC powerfully triggers effector and antigen-presenting functions of macrophages and enhances T cell cytotoxicity. J Leukoc Biol. 2004;75(1):135–142.
   PubMed Web of Science ®Google Scholar
• Boot RG, Hollak CE, Verhoek M, Alberts C, Jonkers RE, Aerts JM. Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. Clin Chim Acta. 2010;411(1–2):31–36.
   PubMed Web of Science ®Google Scholar
• Wang MH, Zhou YQ, Chen YQ. Macrophage-stimulating protein and RON receptor tyrosine kinase: potential regulators of macrophage inflammatory activities. Scand J Immunol. 2002;56(6):545–553.
   Web of Science ®Google Scholar
• Gunella G, Bardelli C, Amoruso A, Viano I, Balbo P, Brunelleschi S. Macrophage-stimulating protein differently affects human alveolar macrophages from smoker and non-smoker patients: evaluation of respiratory burst, cytokine release and NF-κB pathway. Br J Pharmacol. 2006;148(4):478–489.
   Web of Science ®Google Scholar
• Agostini C, Trentin L, Zambello R, et al. CD8 alveolitis in sarcoidosis: incidence, phenotypic characteristics, and clinical features. Am J Med. 1993;95(5):466–472.
   Web of Science ®Google Scholar
• Dubaniewicz A, Trzonkowski P, Dubaniewicz-Wybieralska M, Dubaniewicz A, Singh M, Mysliwski A. Comparative analysis of mycobacterial heat shock proteins-induced apoptosis of peripheral blood mononuclear cells in sarcoidosis and tuberculosis. J Clin Immunol. 2006;26(3):243–250.
   Web of Science ®Google Scholar
• Wahlström J, Berlin M, Sköld CM, Wigzell H, Eklund A, Grunewald J. Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Thorax. 1999;54:339–346.
   PubMed Web of Science ®Google Scholar
• Hill TA, Lightman S, Pantelidis P, Abdallah A, Spagnolo P, du Bois RM. Intracellular cytokine profiles and T cell activation in pulmonary sarcoidosis. Cytokine. 2008;42:289–292.
   PubMed Web of Science ®Google Scholar
• Saltini C, Spurzem JR, Lee JJ, Pinkston P, Crystal RG. Spontaneous release of interleukin 2 by lung T lymphocytes in active pulmonary sarcoidosis is primarily from the Leu3+DR+ T cell subset. J Clin Invest. 1986;77(6):1962–1970.
   PubMed Web of Science ®Google Scholar
• Wahlström J, Dengjel J, Persson B, et al. Identification of HLA- DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest. 2007;117(11):3576–3582.
   PubMed Web of Science ®Google Scholar
• Katchar K, Eklund A, Grunewald J. Expression of Th1 markers by lung accumulated T cells in pulmonary sarcoidosis. J Intern Med. 2003;254:564–571.
   PubMed Web of Science ®Google Scholar
• Nureki S, Miyazaki E, Ando M, et al. Circulating levels of both Th1 and Th2 chemokines are elevated in patients with sarcoidosis. Respir Med. 2008;102:239–247.
   PubMed Web of Science ®Google Scholar
• Zaba LC, Smith GP, Sanchez M, Prystowsky SD, Dendritic cells in the pathogenesis of sarcoidosis. Am J Respir Cell Mol Biol. 2010;42(1):32–39.
   PubMed Web of Science ®Google Scholar
• Tsiligianni I, Antoniou KM, Kyriakou D, et al. Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosis. BMC Pulm Med. 2005;5:8–13.
   Google Scholar
• Sobiecka M, Kus J, Demkow U, et al. Induced sputum in patients with interstitial lung disease: a non-invasive surrogate for certain parameters in bronchoalveolar lavage fluid. J Physiol Pharmacol. 2008; 59(Suppl 6):645–657.
   Google Scholar
• Pertschuk LP, Silverstein E, Friedland J. Immunohistologic diagnosis of sarcoidosis. Detection of angiotensin-converting enzyme in sarcoid granulomas. Am J Clin Pathol. 1981;75(3):350–354.
   Web of Science ®Google Scholar
• Brice EA, Friedlander W, Bateman ED, Kirsch RE. Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD. Chest. 1995;107(3):706–710.
   PubMed Web of Science ®Google Scholar
• Biller H, Ruprecht B, Gaede KI, Müller-Quernheim J, Zissel G. Gene polymorphisms of ACE and the angiotensin receptor AT2R1 influence serum ACE levels in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):139–146.
   Web of Science ®Google Scholar
• Allen RK, Pierce RJ, Barter CE. Angiotensin-converting enzyme in bronchoalveolar lavage fluid in sarcoidosis. Sarcoidosis. 1992;9(1):54–59.
   PubMedGoogle Scholar
• Tahmoush AJ, Amir MS, Connor WW, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):191–197.
   PubMed Web of Science ®Google Scholar
• Miyoshi S, Hamada H, Kadowaki T, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest. 2010;137(6):1391–1397.
   PubMed Web of Science ®Google Scholar
• Prior C, Barbee RA, Evans PM, et al. Lavage versus serum measurements of lysozyme, angiotensin converting enzyme and other inflammatory markers in pulmonary sarcoidosis. Eur Respir J. 1990;3(10):1146–1154.
   Web of Science ®Google Scholar
• Bargagli E, Maggiorelli C, Rottoli P. Human chitotriosidase: a potential new marker of sarcoidosis severity. Respiration. 2008;76(2):234–238.
   PubMed Web of Science ®Google Scholar
• Eklund A, Blaschke E. Elevated serum neopterin levels in sarcoidosis. Lung. 1986;164(6):325–332.
   Web of Science ®Google Scholar
• Planck A, Eklund A, Grunewald J. Markers of activity in clinically recovered human leukocyte antigen-DR17-positive sarcoidosis patients. Eur Respir J. 2003;21(1):52–57.
   Web of Science ®Google Scholar
• Boot RG, Hollak CE, Verhoek M, Alberts C, Jonkers RE, Aerts JM. Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. Clin Chim Acta. 2010;411(1–2):31–36.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Margollicci M, Perrone A, et al. Chitotriosidase analysis in bronchoalveolar lavage of patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24(1):59–64.
   Web of Science ®Google Scholar
• Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181:360–373.
   PubMed Web of Science ®Google Scholar
• Terashita K, Kato S, Sata M, Inoue S, Nakamura H, Tomoike H. Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology. 2006;11(2):145–151.
   Web of Science ®Google Scholar
• Sofia M, Mormile M, Faraone S, Alifano M, Carratù P, Carratù L. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis. 1995;12(2):118–123.
   Google Scholar
• Letizia C, Danese A, Reale MG, et al. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med. 2001;43(4):257–261.
   Web of Science ®Google Scholar
• O’Connor C, Odlum C, Van Breda A, Power C, Fitzgerald MX. Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis. Thorax. 1988;43(5):393–400.
   PubMed Web of Science ®Google Scholar
• Peros-Golubicic T, Ivicevic A, Bekic A, Alilovic M, Tekavec-Trkanjec J, Smojver-Jezek S. Lung lavage neutrophils, neutrophil elastase and albumin in the prognosis of pulmonary sarcoidosis. Coll Antropol. 2001;25(1):349–355.
   Google Scholar
• Teirstein AS. The Kveim-Siltzbach test. Clin Dermatol. 1986;4(4):154–164.
   Google Scholar
• Parrish S, Turner JF. Diagnosis of sarcoidosis. Dis Mon. 2009;55(11):693–703.
   Google Scholar
• Mishra BB, Poulter LW, Janossy G, Sherlock S, James DG. The Kveim-Siltzbach granuloma. A model for sarcoid granuloma formation. Ann N Y Acad Sci. 1986;465:164–175.
   Web of Science ®Google Scholar
• Ahmadzai H, Thomas PS, Wakefield D. Chapter 9. Laboratory investigations and immunological testing in sarcoidosis. In: Eishi Y, editor. Sarcoidosis. Rijeka, Croatia: InTech Open Access Publishing; 2013:201–237.
   Google Scholar
• Lyons DJ, Donald S, Mitchell DN, Asherson GL. Chemical inactivation of the Kveim reagent. Respiration. 1992;59:22–26.
   Web of Science ®Google Scholar
• Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase–peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201(5):755–767.
   PubMed Web of Science ®Google Scholar
• Dubaniewicz A, Kämpfer S, Singh M. Serum anti-mycobacterial heat shock proteins antibodies in sarcoidosis and tuberculosis. Tuberculosis (Edinb). 2006;86(1):60–67.
   Web of Science ®Google Scholar
• Detanico T, Rodrigues L, Sabritto AC. Mycobacterial heat shock protein 70 induces interleukin-10 production: immunomodulation of synovial cell cytokine profile and dendritic cell maturation. Clin Exp Immunol. 2004;135(2):336–342.
   PubMed Web of Science ®Google Scholar
• Dubaniewicz A, Dubaniewicz-Wybieralska M, Sternau A. Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. J Clin Microbiol. 2006;44(9):3448–3451.
   PubMed Web of Science ®Google Scholar
• Dubaniewicz A, Holownia A, Kalinowski L, Wybieralska M, Dobrucki IT, Singh M. Is mycobacterial heat shock protein 16 kDa, a marker of the dormant stage of Mycobacterium tuberculosis, a sarcoid antigen? Hum Immunol. 2013;74(1):45–51.
   Web of Science ®Google Scholar
• Dubaniewicz A, Trzonkowski P, Dubaniewicz-Wybieralska M, Dubaniewicz A, Singh M, Mysliwski A. Mycobacterial heat shock protein-induced blood T lymphocytes subsets and cytokine pattern: comparison of sarcoidosis with tuberculosis and healthy controls. Respirology. 2007;12(3):346–354.
   Web of Science ®Google Scholar
• Magi B, Bini L, Perari MG, et al. Bronchoalveolar lavage fluid protein composition in patients with sarcoidosis and idiopathic pulmonary fibrosis: a two-dimensional electrophoretic study. Electrophoresis. 2002;23(19):3434–3444.
   Web of Science ®Google Scholar
• Rottoli P, Magi B, Perari MG, et al. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics. 2005;5:1423–1430.
   PubMed Web of Science ®Google Scholar
• Silva E, Souchelnytskyi S, Kasuga K, Eklund A, Grunewald J, Wheelock ÅM. Quantitative intact proteomics investigations of alveolar macrophages in sarcoidosis. Eur Respir J. 2013;41(6):1331–1339.
   PubMed Web of Science ®Google Scholar
• Dubaniewicz A, Typiak M, Wybieralska M, et al. Changed phagocytic activity and pattern of Fcγ and complement receptors on blood monocytes in sarcoidosis. Hum Immunol. 2012;73(8):788–794.
   PubMed Web of Science ®Google Scholar
• Sabounchi-Schütt F, Aström J, Hellman U, Eklund A, Grunewald J. Changes in bronchoalveolar lavage fluid proteins in sarcoidosis: a proteomics approach. Eur Respir J. 2003;21(3):414–420.
   Web of Science ®Google Scholar
• Sabounchi-Schütt F, Mikko M, Eklund A, Grunewald J, Aström J. Serum protein pattern in sarcoidosis analysed by a proteomics approach. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(3):182–190.
   Web of Science ®Google Scholar
• Silva E, Bourin S, Sabounchi-Schütt F, et al. A quantitative proteomic analysis of soluble bronchoalveolar fluid proteins from patients with sarcoidosis and chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24(1):24–32.
   PubMed Web of Science ®Google Scholar
• Bons JA, Drent M, Bouwman FG, Mariman EC, van Dieijen-Visser MP, Wodzig WK. Potential biomarkers for diagnosis of sarcoidosis using proteomics in serum. Respir Med. 2007;101(8):1687–1695.
   PubMed Web of Science ®Google Scholar
• Kriegova E, Melle C, Kolek V, et al. Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 2006;173(10):1145–1154.
   Web of Science ®Google Scholar
• Moodley YP, Chetty R, Lalloo UG. Nitric oxide levels in exhaled air and inducible nitric oxide synthase immunolocalization in pulmonary sarcoidosis. Eur Respir J. 1999;14(4):822–827.
   Web of Science ®Google Scholar
• Choi J, Hoffman LA, Sethi JM, Zullo TG, Gibson KF. Multiple flow rates measurement of exhaled nitric oxide in patients with sarcoidosis: a pilot feasibility study. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):98–109.
   PubMed Web of Science ®Google Scholar
• Ciarleglio G, Refini RM, Pieroni MG, et al. Exhaled carbon monoxide in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25(1):46–50.
   Web of Science ®Google Scholar
• Ahmadzai H, Huang S, Hettiarachchi R, Lin JL, Thomas PS, Zhang Q. Exhaled breath condensate: a comprehensive update. Clin Chem Lab Med. 2013;51(7):1343–1361.
   Web of Science ®Google Scholar
• Jackson AS, Sandrini A, Campbell C, Chow S, Thomas PS, Yates DH. Comparison of biomarkers in exhaled breath condensate and bronchoalveolar lavage. Am J Respir Crit Care Med. 2007;175:222–227.
   PubMed Web of Science ®Google Scholar
• Rozyi A, Czerniawska J, Stepniewska A, et al. Inflammatory markers in the exhaled breath condensate of patients with pulmonary sarcoidosis. J Physiol Pharmacol. 2006;57(Suppl 4):335–340.
   Google Scholar
• Nakamura K, Mikuniya M, Takanashi S, et al. Is analysis of exhaled breath condensate an equivalent to bronchoalveolar lavage fluid in sarcoidosis patients? Hirosaki Med J. 2012;63(1):12–20.
   Google Scholar
• Kowalska A, Puscinska E, Czerniawska J, et al. [Markers of fibrosis and inflammation in exhaled breathcondensate (EBC) and bronchoalveolar lavage fluid (BALF) of patients with pulmonary sarcoidosis: a pilot study]. Pneumonol Alergol Pol. 2010;78(5):356–362. Polish.
   Google Scholar
• Ahmadzai H, Cameron B, Chui J, Lloyd A, Wakefield D, Thomas PS. Measurement of neopterin, TGF-β1 and ACE in the exhaled breath condensate of patients with sarcoidosis. J Breath Res. 2013;7(4):046003.
   Web of Science ®Google Scholar
• Psathakis K, Papatheodorou G, Plataki M, et al. 8-Isoprostane, a marker of oxidative stress, is increased in the expired breath condensate of patients with pulmonary sarcoidosis. Chest. 2004;125:1005–1011.
   PubMed Web of Science ®Google Scholar
• Antczak A, Piotrowski W, Marczak J, Ciebiada M, Gorski P, Barnes PJ. Correlation between eicosanoids in bronchoalveolar lavage fluid and in exhaled breath condensate. Dis Markers. 2011; 30(5):213–220.
   Web of Science ®Google Scholar
• Piotrowski WJ, Kurmanowska Z, Antczak A, Marczak J, Górski P. Exhaled 8-isoprostane as a prognostic marker in sarcoidois. A short term follow up. BMC Pulm Med. 2010;10:23–29.
   Web of Science ®Google Scholar
• Kwiatkowska S, Luczynska M, Grzelewska-Rzymowska I, Nowak D, Zieba M. [Comparison of oxidative stress markers in exhaled breath condensate and in serum of patients with tuberculosis and sarcoidosis]. Pol Merkur Lekarski. 2005;19(109):37–40. Polish.
   Google Scholar
• Culver DA. Sarcoidosis. Immunol Allergy Clin North Am. 2012;32(4):487–511.
   Web of Science ®Google Scholar
• Grunewald J. Review: role of genetics in susceptibility and outcome of sarcoidosis. Semin Respir Crit Care Med. 2010;31(4):380–389.
   Web of Science ®Google Scholar
• Jung M, Schaefer A, Steiner I, et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem. 2010;56(6):998–1006.
   PubMed Web of Science ®Google Scholar
• Crouser ED, Julian MW, Crawford M, et al. Differential expression of microRNA and predicted targets in pulmonary sarcoidosis. Biochem Biophys Res Commun. 2012;417(2):886–891.
   Web of Science ®Google Scholar
• Nathans R, Chu CY, Serquina AK, Lu CC, Cao H, Rana TM. Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell. 2009;34(6):696–709.
   PubMed Web of Science ®Google Scholar
• Ma F, Xu S, Liu X, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nat Immunol. 2011;12(9):861–869.
   PubMed Web of Science ®Google Scholar